Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2007-01-16
2007-01-16
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S093200, C424S215100
Reexamination Certificate
active
10704531
ABSTRACT:
Methods for treating proliferative disorders, by administering reovirus to a ral-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts target cancer cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), other serotypes or strains of reovirus, and recombinant reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
REFERENCES:
patent: 5023252 (1991-06-01), Hseih
patent: 6110461 (2000-08-01), Lee et al.
patent: 6136307 (2000-10-01), Lee et al.
patent: 6261555 (2001-07-01), Lee et al.
patent: 6344195 (2002-02-01), Lee et al.
patent: 6455038 (2002-09-01), Lee et al.
patent: 6565831 (2003-05-01), Coffey et al.
patent: 6811775 (2004-11-01), Lee et al.
patent: 2002/0187125 (2002-12-01), Lee et al.
patent: 2003/0003080 (2003-01-01), Lee et al.
patent: 2004/0265271 (2004-12-01), Lee et al.
patent: WO 9908692 (1999-02-01), None
Hamad et al. Genes & Development 2002, vol. 16, pp. 2045-2057.
Urano et al. The EMBO Journal 1996, vol. 15, No. 4, pp. 810-818,
Strong et al. The EMBO Journal 1998, vol. 17, No. 12, pp. 3351-3362.
Hirasawa et al. Cancer Research 2002, vol. 62, pp. 1696-1701.
Hofer et al. Brief. Comminucation 1998, pp. 839-842 plus S1-S2.
Norman et al. PNAS Jul. 2004, vol. 10, No. 30, pp. 11099-11104.
Aronheim, A. et al. (1994). Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the Ras signaling Pathway.Cell78:949-961.
Barbacid, M. (1987).Annu. Rev. Biochem. 56:779-827.
Berrozpe, G. et al. (1994). Comparative analysis of Mutations in the p53 and K-ras genes.Int. J. Cancer58:185-191.
Bischoff, J.R. and Samuel, C.E. (1989). Mechanism of interferon action: activation of the human P1/eIF-2aα protein kinase by individual reovirus s-class mRNAs: s1 mRNA is a potent activator relative to s4 mRNA.Virology172:106-115.
Bos, J.L. (1989). ras Oncogenes in human cancer: a review.Cancer Res. 49:4682-4689.
Bos, J.L. (1998). All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral.EMBO J. 17:6776-6782.
Cahill, M.A. et al. (1996). Signalling pathways. Jack of all cascades.Curr. Biol. 6:16-19.
Chandran, K. and Nibert M.L. (1998). Protease cleavage of reovirus capsid protein μ1/μ1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subvirion particle.J. Virol. 72:467-475.
Chaubert, P. et al. (1994). K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis.Am. J. Path. 144:767-775.
Cuff, C.F. et al. (1998). Enteric reovirus infection as a probe to study immunotoxicity of the gastrointestinal tract.Toxicological Sciences42:99-108.
de Ruiter, N.D. et al. (2000). Ras-dependent regulation of c-Jun phosphorylation is mediated by the Ral guanine nucleotide exchange factor-Ral pathway.Mol. Cell Biol. 20:8480-88.
Der, S.D. et al. (1997). A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis.Proc. Natl. Acad. Sci. U.S.A. 94:3279-3283.
Dudley, D.T. et al. (1995). A synthetic inhibitor of the mitogen-activated protein kinase cascase.Proc. Natl. Acad. Sci. U.S.A. 92:7686-7689.
Duncan, R. et al. (1991). Conformational and functional analysis of the C-terminal globular head of the reovirus cell attachment protein.Virology182:810-819.
Helbing, C.C. et al. (1997). A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis.Cancer Res. 57:1255-1258.
Hirasawa, K. et al. (2002). Oncolytic reovirus against ovarian and colon cancer.Cancer Research62:1696-1701.
Hu, Y. and Conway, T.W. (1993), 2-aminopurine inhibits the double-stranded RNA-dependent protein kinase bothin vitroandin vivo. J. Interferon Res. 13:323-328.
Janes, P.W. et al. (1994). Activation of the Ras signalling pathway in human breast cancer cells overexpressingerbB-2.Oncogene9:3601-3608.
Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4.Nature227:680-685.
Lee, J.M. et al. (1993). p53 mutations increase resistance to ionizing radiation.Proc. Natl. Acad. Sci. U.S.A. 90:5742-5746.
Lee, P.W.K. et al. (1981). Characterization of anti-reovirus immunoglobulins secreted by cloned hybridoma cell lines.Virology108:134-146.
Levitzki, A. (1994). Signal-transduction therapy: a novel approach to disease management.Eur. J. Biochem. 226:1-13.
Lowe, S.W. et al. (1994). p53 status and the efficacy of cancer therapyin vivo. Science266:807-810.
Mah, D.C. et al. (1990). The N-terminal quarter of reovirus cell attachment protein δ1 possesses intrinsic virion-anchoring function.Virology179:95-103.
McCrae, M.A. and Joklik, W.K. (1978). The nature of the polypeptide encoded by each of the 10 double-stranded RNA segments of reovirus type 3.Virology89:578-593.
Mills, N.E. et al. (1995). Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma.Cancer Res. 55:1444-1447.
Mundschau, L.J. and Faller, D.V. (1992). Oncogenicrasinduces an inhibitor of double-stranded RNA-dependent eukaryotic initiation factor 2α-kinase activation.J. Biol. Chem. 267:23092-98.
Nagata, L. et al. (1984). Molecular cloning and sequencing of the reovirus (serotype 3) S1 gene which encodes the viral cell attachment protein δ1.Nucleic Acids Res. 12:8699-8710.
Nedergaard, T. et al. (1997). A one-step DGGE scanning method for detection of mutations in the K-,N-, and H-ras oncogenes: mutations at codons 12,13 and 61 are rare in B-cell non-Hodgkin's lymphoma.Int. J. Cancer. 71:364-9.
Nibert, M.L., et al., (1996). Reoviruses and their replication.Fields Virology, 3rdEdition, Lippincott-Raven Publishers, pp. 1557-1596.
Raybaud-Diogene, H. et al. (1997). Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study.J. Clin. Oncology, 15:1030-1038.
Robinson, M.J. and Cobb, M.H. (1997). Mitogen-activated protein kinase pathways.Curr. Opin. Cell. Biol. 9:180-186.
Rosen, L. (1960). Serologic grouping of reoviruses by hemagglutination-inhibition.Am. J. Hyg. 71:242-249.
Sabin, A.B. (1959). Science in the news.Science130:966-972.
Samuel, C.E. and Brody, M.S. (1990). Biosynthesis of reovirus-specified polypeptides.Virology176:106-113.
Smith, R.E. et al. (1969). Polypeptide components of virions, top component and cores of reovirus type 3.Virology39:791-810.
Stanley, N.F. (1967). Reoviruses.Br. Med. Bull. 23:150-154.
Strong, J.E. et al. (1993). Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency.Virology197:405-411.
Strong, J.E. amd Lee, P.W.K. (1996). Thev-erbB oncogene confers enhanced cellular susceptibility to reovirus infection.J. Virol. 70:612-616.
Trimble, W.S. et al. (1986). Inducible cellular transformation by a metallothionein-rashybrid oncogene leads to natural killer cell susceptibility.Nature321:782-784.
Turner, D.L. et al. (1992) Site directed mutagenesis of the C-terminal portion of reovirus protein δ1 evidence for a conformation-dependent receptor binding domain.Virology186:219-227.
Tweeddale, M.E. et al. (1987). The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor.Blood69:1307-14.
Vojtek, A.B. amd Der, C.J.. (1998). Increasing complexity of the Ras signaling pathway.J. Biol. Chem. 273:19925-28.
Ward, Y.. et al. (2001). Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways.Mol. Cell Biol. 21:5958-69.
Waters, S.D. et al. (1995). Desensitization of Ras activation by a feedback disassociation of the Sos-Grb2 complex.J. Biol. Chem. 270-208
Lee Patrick W. K.
Norman Kara L.
Campell Bruce R.
Fish & Richardson P.C.
Li Bao Qun
Oncolytics Biotech Inc.
LandOfFree
Reovirus for the treatment of ral-mediated cellular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reovirus for the treatment of ral-mediated cellular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reovirus for the treatment of ral-mediated cellular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3753379